L
Lixin Pharmaceutical Technology
A clinical-stage biotech company focused on discovering and developing innovative biologic drugs for cancer treatment
About Lixin Pharmaceutical Technology
LaNova Medicines, founded in 2019, is a research-driven biotech company specializing in the discovery and development of antibody-based cancer treatments. The company operates in the oncology sector, targeting both the Chinese and global markets. LaNova's business model revolves around leveraging its proprietary platforms and distinctive development strategies to create a robust pipeline of differentiated programs. These programs are driven forward into clinical stages with unmatched speed and efficiency, setting industry standards. LaNova serves patients with various types of cancer, including pancreatic, gastric, and gastroesophageal junction cancers. The company generates revenue through licensing agreements, such as the one with Turning Point Therapeutics for LM 302, and through funding rounds, like the Series B financing closed in June 2022. LaNova's seasoned management team brings decades of leadership experience in multinational pharmaceutical and local biotech organizations, providing a unique perspective on both the Chinese market and the global arena.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2019
- Headquarters
- Huangpu, China
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 74.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2025 | $951M | $1B | Sino Biopharmaceutical | ↗ |
| SERIES COther financing | Oct 2024 | $41M | $248M | Qiming Venture Partners · Zhangjiang Hi-Tech Park · SHC Shanghai Biomedical Fund · Sino Biopharmaceutical | ↗ |
Growth signals
Latest recorded traffic for Lixin Pharmaceutical Technology is 2.4K monthly website visits, up 84.6% over the last three months. Lixin Pharmaceutical Technology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Hangzhou Tigermed
Yingke Capital
Series A3 investors entered at this stage
Qiming Venture Partners
Asymchem
Summer Capital
Series B and later5 investors entered at this stage
Spinnotec- ZPZhangjiang Hi-Tech Park
Sino Biopharmaceutical
SHC Shanghai Biomedical Fund- PCPudong Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lixin Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lixin Pharmaceutical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.